Melatonin treatment improves primary progressive multiple sclerosis: a case report

被引:48
|
作者
Lopez-Gonzalez, Antonio [1 ,2 ]
Alvarez-Sanchez, Nuria [3 ]
Lardone, Patricia J. [3 ,4 ]
Cruz-Chamorro, Ivan [3 ,4 ]
Martinez-Lopez, Alicia [3 ]
Guerrero, Juan M. [3 ,4 ,5 ]
Reiter, Russel J. [6 ]
Carrillo-Vico, Antonio [3 ,4 ]
机构
[1] Virgen Macarena Univ Hosp, Dept Neurosurg, Seville, Spain
[2] Virgen del Rocio Univ Hosp, Dept Neurosurg, Seville, Spain
[3] Univ Seville, CSIC, Virgen del Rocio Univ Hosp, Inst Biomed Seville IBiS, Seville 41013, Spain
[4] Univ Seville, Sch Med, Dept Med Biochem Mol Biol & Immunol, Seville 41013, Spain
[5] Virgen del Rocio Univ Hosp, Dept Clin Biochem, Seville, Spain
[6] UT Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX USA
关键词
melatonin; multiple sclerosis; primary progressive multiple sclerosis; OXIDATIVE DAMAGE; NATURAL-HISTORY; NERVOUS-SYSTEM; EXPRESSION; ANTIOXIDANT; PREVALENCE; CELLS; GENETICS; ETIOLOGY; STRESS;
D O I
10.1111/jpi.12203
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We describe the case of a female patient who, at the age of 28, was diagnosed with symptoms of primary progressive multiple sclerosis (PPMS). Glucocorticoid treatment was immediately initiated. The disease and the demyelinating lesions progressed during the following 9 years reaching Expanded Disability Status Scale (EDSS) 8.0 (patient essentially restricted to bed, a chair or perambulated in a wheelchair). At this point, the patient began taking melatonin at doses ranging from 50 to 300 mg per day. Melatonin was her only treatment for the next 4 years; during this interval, her EDSS progressively recovered to 6.0 (the person needs intermittent or unilateral constant assistance such as cane, crutch, or brace to walk 100 meters with or without resting). This long-lasting improvement is likely due to melatonin usage since it is related in time and because of its exceptionally long duration.
引用
收藏
页码:173 / 177
页数:5
相关论文
共 50 条
  • [41] Treatment with electromagnetic fields alters the clinical course of chronic progressive multiple sclerosis - A case report
    Sandyk, R
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 1996, 88 (1-2) : 75 - 82
  • [42] Intravenous immunoglobulin treatment for patients with primary or secondary progressive multiple sclerosis
    Pöhlau, D
    Przuntek, H
    Späth, P
    Andresen, I
    MULTIPLE SCLEROSIS, 2005, 11 : S163 - S163
  • [43] SOCIOECONOMIC VALUE OF OCRELIZUMAB IN THE TREATMENT OF PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
    Di Maio, D.
    Wu, J.
    Stavropoulos, A.
    Sanchez, Alvarez J.
    Diles, D.
    VALUE IN HEALTH, 2021, 24 : S161 - S161
  • [44] Intravenous immunoglobulin treatment for patients with primary or secondary progressive multiple sclerosis
    Pöhlau, D
    Kallweit, U
    INTRAVENOUS IMMUNOGLOBULINS IN THE THIRD MILLENNIUM, 2004, : 235 - 241
  • [45] SOCIOECONOMIC VALUE OF OCRELIZUMAB IN THE TREATMENT OF PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
    Di Maio, D.
    Liu, C.
    Marcelli, G.
    Alvarez, Sanchez J.
    Overell, J.
    VALUE IN HEALTH, 2020, 23 : S632 - S633
  • [48] Guanidinoacetate-creatine in secondary progressive multiple sclerosis: a case report
    Ostojic, Sergej M.
    Ostojic, Jelena
    Zanini, Dragana
    Jezdimirovic, Tatjana
    Stajer, Valdemar
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2022, 50 (01)
  • [49] A CASE OF UNIHEMISPHERIC PROGRESSIVE MULTIPLE SCLEROSIS
    Furby, J.
    Giovannoni, G.
    Page, R.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2012, 83
  • [50] Progressive dopaminergic defect in a patient with primary progressive multiple sclerosis
    Kaasinen, Valtteri
    Joutsa, Juho
    Rissanen, Eero
    Airas, Laura
    Soilu-Hanninen, Merja
    Noponen, Tommi
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 36